Clinical Trial Update: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update about using hepatic arterial infusion chemotherapy (HAIC) with subsequent transarterial embolization (TAE) in combination with t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Surufatinib (Surufatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING